Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PBYI Relative to the S&P 500

PBYI Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Puma Biotechnology, Inc. (NASD:PBYI) seasonal charts above shows that a Buy Date of January 2 and a Sell Date of March 22 has resulted in a geometric average return of 3.06% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 28.04% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

To download PBYI seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PBYI